Neurology and Neurosurgery - Global Neurology Academy

Episodes 17-32 of 413

Advances in the Treatment of Neuropsychiatric Symptoms of Alzheimer's Disease: Early Recognition, Diagnosis, and Innovative Emerging Therapies
Advances in the Treatment of Neuropsychiatric Symptoms of Alzheimer's Disease: Early Recognition, Diagnosis, and Innovative Emerging Therapies
CME/CE
Advances in the Treatment of Neuropsychiatric Symptoms of Alzheimer's Disease: Early Recognition, Diagnosis, and Innovative Emerging Therapies
1.00 credit
- Marwan Sabbagh, MD, FAAN
- Alireza Atri, MD, PhD
- Christoph U. Correll, MD
1.00 credit
Evaluating MenB Vaccines Beyond the Traditional hSBA Assay
Evaluating MenB Vaccines Beyond the Traditional hSBA Assay
Global Neurology Academy
Evaluating MenB Vaccines Beyond the Traditional hSBA Assay
The Future of MS Management: Novel Agents and Clinical Approaches
The Future of MS Management: Novel Agents and Clinical Approaches
NeuroFrontiers
The Future of MS Management: Novel Agents and Clinical Approaches
- Marisa McGinley, DO
MS Relapse vs Pseudo-Relapse After Infection: COVID-19 Shows Divergent Risk Pattern
MS Relapse vs Pseudo-Relapse After Infection: COVID-19 Shows Divergent Risk Pattern
NeuroFrontiers
MS Relapse vs Pseudo-Relapse After Infection: COVID-19 Shows Divergent Risk Pattern
Pregnancy and Infant Outcomes in Multiple Sclerosis: Findings From the MAPLE-MS Pharmacovigilance Program
Pregnancy and Infant Outcomes in Multiple Sclerosis: Findings From the MAPLE-MS Pharmacovigilance Program
NeuroFrontiers
Pregnancy and Infant Outcomes in Multiple Sclerosis: Findings From the MAPLE-MS Pharmacovigilance Program
Reevaluating Natalizumab Dosing in RRMS: Insights from the NOVA Trial
Reevaluating Natalizumab Dosing in RRMS: Insights from the NOVA Trial
NeuroFrontiers
Reevaluating Natalizumab Dosing in RRMS: Insights from the NOVA Trial
Recognizing MS: Understanding Symptoms and Avoiding Misdiagnosis
Recognizing MS: Understanding Symptoms and Avoiding Misdiagnosis
NeuroFrontiers
Recognizing MS: Understanding Symptoms and Avoiding Misdiagnosis
Modern MS Care: Navigating Treatment Options for Better Patient Outcomes
Modern MS Care: Navigating Treatment Options for Better Patient Outcomes
NeuroFrontiers
Modern MS Care: Navigating Treatment Options for Better Patient Outcomes
Epigenetic Immune Signatures in Alzheimer’s: Implications for Diagnosis and Therapy
Epigenetic Immune Signatures in Alzheimer’s: Implications for Diagnosis and Therapy
NeuroFrontiers
Epigenetic Immune Signatures in Alzheimer’s: Implications for Diagnosis and Therapy
- David Gate, PhD
Understanding MS: Managing Hidden and Overlooked Symptoms
Understanding MS: Managing Hidden and Overlooked Symptoms
Global Neurology Academy
Understanding MS: Managing Hidden and Overlooked Symptoms
- Marisa McGinley, DO
Advancing MS Care: Evolving Treatments and High-Efficacy Approaches
Advancing MS Care: Evolving Treatments and High-Efficacy Approaches
NeuroFrontiers
Advancing MS Care: Evolving Treatments and High-Efficacy Approaches
- Marisa McGinley, DO
Recognizing the Full Spectrum of MS Symptoms: Multidisciplinary Pathways to Better Care
Recognizing the Full Spectrum of MS Symptoms: Multidisciplinary Pathways to Better Care
NeuroFrontiers
Recognizing the Full Spectrum of MS Symptoms: Multidisciplinary Pathways to Better Care
- Marisa McGinley, DO
ASD in Children with SMA Type I: Diagnostic Challenges in a Multifactorial Context
ASD in Children with SMA Type I: Diagnostic Challenges in a Multifactorial Context
NeuroFrontiers
ASD in Children with SMA Type I: Diagnostic Challenges in a Multifactorial Context
Safety and Efficacy of Onasemnogene Abeparvovec in Pediatric SMA Across Expanded Weight Cohorts
Safety and Efficacy of Onasemnogene Abeparvovec in Pediatric SMA Across Expanded Weight Cohorts
NeuroFrontiers
Safety and Efficacy of Onasemnogene Abeparvovec in Pediatric SMA Across Expanded Weight Cohorts
New-Onset Ketosis-Prone Diabetes in an Adult with Spinal Muscular Atrophy Type III
New-Onset Ketosis-Prone Diabetes in an Adult with Spinal Muscular Atrophy Type III
NeuroFrontiers
New-Onset Ketosis-Prone Diabetes in an Adult with Spinal Muscular Atrophy Type III
Reevaluating Spinal Muscular Atrophy Therapy: Signs, Tools, and Strategies
Reevaluating Spinal Muscular Atrophy Therapy: Signs, Tools, and Strategies
NeuroFrontiers
Reevaluating Spinal Muscular Atrophy Therapy: Signs, Tools, and Strategies
- Brian P. McDonough, MD, FAAFP
- Nancy Kuntz, MD

2/7